ClinVar Miner

Submissions for variant NM_000059.3(BRCA2):c.9096A>C (p.Lys3032Asn) (rs864622582)

Minimum review status: Collection method:
Minimum conflict level:
ClinVar version:
Total submissions: 2
Download table as spreadsheet
Submitter RCV SCV Clinical significance Condition Last evaluated Review status Method Comment
GeneDx RCV000236934 SCV000293607 uncertain significance not provided 2015-11-25 criteria provided, single submitter clinical testing This variant is denoted BRCA2 c.9096A>C at the cDNA level, p.Lys3032Asn (K3032N) at the protein level, and results in the change of a Lysine to an Asparagine (AAA>AAC). Using alternate nomenclature, this variant would be defined as BRCA2 9324A>C. This variant has not, to our knowledge, been published in the literature as pathogenic or benign. BRCA2 Lys3032Asn was not observed in approximately 6,500 individuals of European and African American ancestry in the NHLBI Exome Sequencing Project, suggesting it is not a common benign variant in these populations. Since Lysine and Asparagine differ in some properties, this is considered a semi-conservative amino acid substitution. BRCA2 Lys3032Asn occurs at a position where amino acids with properties similar to Lysine are tolerated across species and is located in the DNA binding domain (Borg 2010). In silico analyses are inconsistent regarding the effect this variant may have on protein structure and function. Based on currently available evidence, it is unclear whether BRCA2 Lys3032Asn is a pathogenic or benign variant. We consider it to be a variant of uncertain significance.
Invitae RCV000204782 SCV000261203 uncertain significance Hereditary breast and ovarian cancer syndrome 2018-02-25 criteria provided, single submitter clinical testing This sequence change replaces lysine with asparagine at codon 3032 of the BRCA2 protein (p.Lys3032Asn). The lysine residue is highly conserved and there is a moderate physicochemical difference between lysine and asparagine. This variant is not present in population databases (ExAC no frequency). This variant has not been reported in the literature in individuals with a BRCA2-related disease. ClinVar contains an entry for this variant (Variation ID: 220564). Algorithms developed to predict the effect of missense changes on protein structure and function output the following: SIFT: "Deleterious"; PolyPhen-2: "Benign"; Align-GVGD: "Class C0". The asparagine amino acid residue is found in multiple mammalian species, suggesting that this missense change does not adversely affect protein function. These predictions have not been confirmed by published functional studies and their clinical significance is uncertain. In summary, this variant has uncertain impact on BRCA2 function. The available evidence is currently insufficient to determine its role in disease. Therefore, it has been classified as a Variant of Uncertain Significance.

The information on this website is not intended for direct diagnostic use or medical decision-making without review by a genetics professional. Individuals should not change their health behavior solely on the basis of information contained on this website. Neither the University of Utah nor the National Institutes of Health independently verfies the submitted information. If you have questions about the information contained on this website, please see a health care professional.